IPD capsules 100 (asthma, atopic dermatitis, allergic rhinitis)

General information on Japanese IPD capsules 100 (asthma, atopic dermatitis, allergic rhinitis)     

CURRENTLY UNAVAILABLE!

Package details: 100 capsules

Manufacturer: Taiho Pharmaceutical Co. Ltd., Japan

Active ingredient: suplatast tosilate (chemical formula C23H33NO7S2)

Medical effect: IPD capsules 100 are effective for the treatment of the following diseases and conditions:

1. bronchial asthma,
2. atopic dermatitis,
3. allergic rhinitis,
4. hyperimmunoglobulinemia E,
5. Kimura’s disease.

Contraindications and precautions: do not use in pregnant or breastfeeding women. Do not use for patients with liver damage.

 If an allergic reaction occurs, stop using the medication and consult with your doctor. If you’re taking any other medication, please consult with your doctor before use.

Dosage and administration of Japanese IPD capsules 100 (asthma, atopic dermatitis, allergic rhinitis)

For adults, take 1 capsule 3 times a day after meals.

The dosage may be adjusted by the consulting doctor according to age, body weight and symptoms.

How effective are IPD capsules 100 from Japan (asthma, atopic dermatitis, allergic rhinitis)?

IPD capsules contain 100 mg of suplatast tosilate, a Th2 cytokine inhibitor. It works by inhibiting the infiltration of lymphocytes including CD4+ T cells into healthy tissues, like lungs or broncho-bronchiolar walls. As the result, IPD capsules prevent the expression of the allergic reaction without affecting the positivity for specific IgE antibodies against allergens.

Who should use IPD capsules 100 from Japan?

IPD capsules 100 with suplatast tosilate are a new anti-allergic drug capable of down-regulating the functions of lymphocytes. They are effective against bronchial asthma, atopic dermatitis, allergic rhinitis, hyperimmunoglobulinemia E and Kimura’s disease. Studies show that treatment with a IPD capsules in steroid-dependent asthma improves pulmonary function and symptom control, and allows a decrease in dose of inhaled corticosteroid without significant side-effects (J. Tamaoki, M. Kondo, N. Sakai, et al. Effect of suplatast tosilate, a Th2 cytokine inhibitor, on steroid-dependent asthma: a double-blind randomised study // Lancet, 200, July, 356 (9226): 273–8). However, this medicine is not designed to rapidly alleviate already occurring asthma attacks or symptoms.